

A new Board has been appointed at NanoEcho - increased focus on commercialization

A new Board that reflects the Company's development has been appointed. The newly appointed Chairman is Daniel Johnsson, former CEO and founder of, among others, Exertis Nordics, now investor and advisor. A new member of the Company's Board is PhD and Business Coach Ann-Christin Malmberg Hager.

At the Annual General Meeting, NanoEcho elected Daniel Johnsson as Chairman of the Board. Daniel is a serial entrepreneur, former CEO and founder of Exertis Nordics (formerly known as CapTech Distribution), a profitable, fast-growing gazelle company that today is one of the Nordic region's largest distributors of IT, AV and multimedia products. Under the leadership of Daniel, the Company's sales grew from SEK 0 to 3 billion. Daniel currently works as an investor, board professional and advisor.

Also new to the Board is Ann-Christin Malmberg Hager, who has solid experience as CEO of development companies, most recently as CEO of PainDrainer and before that as CEO of SenzaGen for 5 years. Under the leadership of Ann-Christin, SenzaGen developed animal-free allergy testing, from an innovation to the Company entering the commercial stage and being listed on Nasdaq First North. Led by Ann-Christin, the Company's market capitalization increased from MSEK 5 to 500. Today, Ann-Christin works as a consultant and business coach for SmiLe Life Science Incubator.

Furthermore, the board members PhD Johannes Swartling, MBA BG Svensson, and Professor Tomas Jansson were re-elected.

The Company's Board is elected in view of the position shift that the Company has made, from being a research company to being a clear product development company. Today, the Company is fully focused on developing a product for commercialization.

"We are both happy and proud that Daniel has chosen to take on the role of Chairman of the Board of NanoEcho. We really look forward to sharing Daniel's knowledge, network and solid experience of building profitable companies." – says Linda Persson, CEO of NanoEcho.

"I see great potential in NanoEcho's system and I really believe in the Company. I look forward to supporting them in the work of launching a product in the market that improves the quality of life for people affected by cancer." - says Daniel Johnsson, newly appointed Chairman of the Board of NanoEcho.

For a complete presentation of NanoEcho's Board, see: www.NanoEcho.se

For further information, please contact:

Kristina Hallström, CMO & CCO
email: ir@nanoecho.se

NanoEcho has developed a new technology for clearer diagnostics of, as the first phase, rectal cancer. The imaging technology is based on a new medical approach where nanotechnology is used in combination with modern ultrasound technology. The images that are generated are intended to facilitate differentiation between healthy and diseased tissue and at the same time determine the location of the cancer tissue more precisely. The aim is to provide more precise, simpler and less costly diagnosis of cancers and other diseases. With clearer diagnostics, the company wants to assist treating physicians with better guidance for more personalized treatment. Both the quality of life of the patients and their chance of survival can improve after treatment, with reduced treatment costs.